Evidence map›Paper›PMID 31025053›Full record

Trial reportStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2019

A dedicated cloud system for real-time upfront quality assurance in pediatric radiation therapy.

Silvia Meroni, Claudia Cavatorta, Salvina Barra, Francesca Cavagnetto, Giovanni Scarzello, Alessandro Scaggion, Emilia Pecori, Barbara Diletto, Ombretta Alessandro, Maura Massimino and 3 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Silvia MeroniMedical Physics Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian, 1, 20133, Milano, Italy.
Claudia CavatortaMedical Physics Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian, 1, 20133, Milano, Italy. claudia.cavatorta@istitutotumori.mi.it.
Salvina BarraU.O.S Radioterapia Infantile Policlinico SanMartino, Genova, Italy.
Francesca CavagnettoMedical Physics Unit, Policlinico SanMartino, Genova, Italy.
Giovanni ScarzelloRadiation Therapy Department, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Alessandro ScaggionMedical Physics Department, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
Emilia PecoriPediatric Radiotherapy Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Barbara DilettoPediatric Radiotherapy Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Ombretta AlessandroPediatric Radiotherapy Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Maura MassiminoPediatric Oncology Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Stefano GianoliniMedical Software Solutions GmbH, Hagendorn, Switzerland.
Emanuele PignoliMedical Physics Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Via Giacomo Venezian, 1, 20133, Milano, Italy.
Lorenza GandolaPediatric Radiotherapy Unit, Fondazone IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Fondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Oncologico Veneto · ITMedical Solutions · GBUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePediatric radiotherapy (RT) is a highly specialized field, requiring great experience to delineate correctly tumor targets and organs at risk. To reduce treatment failures related to planning inaccuracies and to obtain robust clinical results despite the limited numbers of enrolled pediatric patients, the SIOP PNET5MB clinical trial on medulloblastoma requires a real-time, pre-radiation review of the RT treatment (craniospinal irradiation and boost plan) under the direct responsibility of the national coordinator center. Here we describe the centralized radiotherapy quality assurance (QA) program developed in Italy for this purpose.

methodsUsing the software package VODCA (MSS, Hagendorn, Switzerland, www.vodca.ch ), we developed a cloud platform able to handle computed tomography (CT) images and RT objects and to support the complete workflow required by the review process in the context of the SIOP PNET5 trial.

resultsAll Italian centers participating in the PNET5 trial adopted the proposed QA system. 24 patients were successfully enrolled and reviewed. For 15 patients (62.5%), one or more plan revisions were requested for the craniospinal irradiation plan and for 11 patients (45.8%) plan revisions were requested for the boost. RT was delivered after the plan was centrally approved for all enrolled patients. So far, in Italy, no patients have been excluded from PNET5 due to dosimetric incompliance to the protocol or for exceeding the RT starting time limit.

conclusionThe cloud platform successfully supported the trial workflow, producing official review documents. This efficient QA was crucial to guarantee optimized treatments and protocol compliance for all pediatric patients enrolled in the SIOP protocol.

Indexed as

Cloud ComputingSpecializationCerebellar NeoplasmsChildHumansMedulloblastomaNeuroectodermal Tumors, PrimitiveOrgans at RiskQuality Assurance, Health CareRadiometryRadiotherapy Planning, Computer-AssistedSoftware DesignWorkflowCraniospinal irradiationMedulloblastomaPediatric radiotherapyQuality assuranceSIOP PNET 5 MB trial

Identifiers

PMID31025053
OpenAlexW2941688402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.